Passage Bio Says New Interim Data From Imagine-1 Clinical Study Strengthens Safety Profile Of PBGM01

RTTNews | Před 880 dny
Passage Bio Says New Interim Data From Imagine-1 Clinical Study Strengthens Safety Profile Of PBGM01

(RTTNews) - Genetic medicines company Passage Bio, Inc. (PASG) announced on Wednesday new interim safety, biomarker, and clinical development results from cohorts 1-3 in the Imagine-1 clinical study.

Imagine-1 is a Phase 1/2, global, open-label, dose-escalation study of the AAVhu68 gene therapy PBGM01 delivered by intra-cisterna magna (ICM) injection in four cohorts of pediatric subjects with early and late infantile GM1 Gangliosidosis (GM1).

GM1 is a rare, fatal lysosomal storage disease in which mutations in the GLB1 gene result in very low activity of the enzyme beta-galactosidase (ß-Gal).

The interim data include six treated patients from the first three cohorts. Cohort 1 (late infantile, low dose), Cohort 2 (late infantile, high dose) and Cohort 3 (early infantile, low dose) each consisted of two patients. Cohort 4 (early infantile, high dose) patients have been dosed and data is expected by mid-2023.

The company noted that new interim data from cohorts 1-3 continue to strengthen the favorable safety profile of PBGM01, with no treatment-related serious adverse events, no complications related to ICM administration and no evidence of DRG toxicity.

Passage has completed dosing of PBGM01 in the dose-escalation portion of the study and will evaluate dosing further patients at the current high dose and/or a higher dose as data from cohorts 1-4 mature.

For More Such Health News, visit rttnews.com

read more
TSX Remains Firmly Up Despite Coming Off Early Highs

TSX Remains Firmly Up Despite Coming Off Early Highs

The Canadian market remains in positive territory Monday afternoon as the mood remains fairly bullion amid easing concerns about tariffs following China and U.S. agreeing on a trade deal.
RTTNews | Před 2 h 56 min
Swiss Market Ends On Bright Note As Stocks Rally On Late Buying

Swiss Market Ends On Bright Note As Stocks Rally On Late Buying

The Switzerland market, which faltered after a marginal upmove at the start and stayed sluggish till well past noon on Monday, climbed higher in late afternoon trade with stocks from across several sectors attracting buyers. News about China and the U.S. agreeing on a trade deal, and the resultant buoyancy in major European markets lifted sentiment in the Swiss market as well.
RTTNews | Před 3 h 26 min
Dollar Extends Gains As Trade Tensions Ease

Dollar Extends Gains As Trade Tensions Ease

It was another positive week for the greenback as easing trade tensions and hopes of a deal with China helped the U.S. Dollar build on gains made in the previous week.
RTTNews | Před 6 h 18 min
Fox Q3 Profit Down, Revenues Climb, Both Ahead Of Market; Stock Gains

Fox Q3 Profit Down, Revenues Climb, Both Ahead Of Market; Stock Gains

Media firm Fox Corp. reported Monday weak earnings in its third quarter on higher expenses, while revenues were higher, benefited mainly by advertising revenue growth of 65 percent, primarily due to the impact of Super Bowl LIX. Adjusted earnings and top line beat market estimates. In pre-market activity on the Nasdaq, the FOX shares were gaining around 3.8 percent.
RTTNews | Před 8 h 0 min
Bay Street Likely To Open On Firm Note

Bay Street Likely To Open On Firm Note

The Canadian market is likely to open with a strong positive gap on Monday, tracking gains in global markets amid easing tariff concerns following China and the U.S. striking a deal over the weekend.
RTTNews | Před 8 h 23 min
U.S., China Reach Agreement To Slash Tariffs

U.S., China Reach Agreement To Slash Tariffs

Following closely watched meetings over the weekend in Geneva, Switzerland, the U.S. and China have announced an agreement to drastically reduce tariffs on each other's goods. The White House said the agreement calls for the U.S. and China to each lower tariffs by 115 percent while retaining an additional 10 percent tariff.
RTTNews | Před 9 h 0 min